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The biological consequences of a carcinogen–DNA adduct are defined by the structure of the
lesion and its position within the genome. Electrospray ionization ion trap mass spectrometry
(ESI-ITMS) is shown here to be a sensitive and rapid approach capable of defining both of
these parameters. Three isomeric oligonucleotides of the sequence 59-CCGGAGGCC modified
by the potent human carcinogen aflatoxin B1 (AFB1) at different guanines were analyzed by
ESI-ITMS. All three samples possessed the same molecular ion confirming the presence of an
intact aflatoxin moiety in each oligonucleotide. In addition, each sample displayed a charac-
teristic fragmentation pattern that permitted unambiguous identification of the site of
modification within the sequence. Furthermore, an AFB1-modified oligonucleotide was
converted under alkaline conditions to its more stable formamidopyrimidine (FAPY) deriva-
tive. Analysis of this sample revealed the presence of a molecular ion corresponding to the
presence of the FAPY adduct and a distinctive fragmentation pattern that paralleled the known
chemical stability of the FAPY metabolite. This approach should be of general use in the
determination of not only the nature and site of covalent modifications, but also the chemical
stability of DNA adducts. (J Am Soc Mass Spectrom 1998, 9, 676–682) © 1998 American
Society for Mass Spectrometry
Mutagens and carcinogens often interact co-valently with DNA to form DNA adducts.Because the biological effects of these DNA
adducts can vary depending on both the structural
nature of the adduct as well as its sequence location, it
is critical to obtain detailed information regarding both
parameters. Traditional approaches to determine DNA
adduct structure involve analysis of the adduct at the
nucleobase or nucleoside level and comparison to
chemically synthesized standards [1]. Unfortunately,
these procedures result in loss of all sequence informa-
tion. Alternatively, some chemical and biological meth-
ods exist to determine the location of an adduct, includ-
ing variations of Maxam–Gilbert sequencing, and DNA
replication or exonuclease mapping [1–3]. However,
these techniques are highly adduct specific and provide
no information regarding the structure of the adduct.
More comprehensive structural approaches, such as
NMR spectroscopy [4, 5] or x-ray crystallography [6, 7]
are prohibitively time and sample intensive and thus of
little practical value for adduct mapping.
Mass spectrometry, by contrast with the aforemen-
tioned techniques, may be able to determine directly the
site of DNA modification and the structure of an adduct
in a sensitive and rapid fashion. Techniques used to
ionize large biomolecules such as oligonucleotides in-
clude fast atom bombardment (FAB) [8], matrix-as-
sisted laser desorption (MALD) [9] and electrospray
(ES) [10, 11]. Electrospray ionization (ESI) has been used
to determine accurately the mass of both unmodified
[12, 13] and modified oligonucleotides [14–18]. Various
carcinogen– and drug–DNA adducts at the nucleotide
level have been characterized by FAB [19–21] as well as
ESI [22] coupled to tandem mass spectrometry.
Electrospray ionization coupled with an ion trap
mass spectrometer (ITMS) has been used to gain se-
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quence information for small unmodified [23–25] and
modified oligonucleotides [26] using multiple stages of
mass spectrometry (MSn). A specific fragmentation
pattern is observed showing loss of the nucleobase and
cleavage of the phosphodiester backbone at the 39 C–O
bond of the depurinated sugar. In addition, it has been
found that electron-withdrawing modifications to the
nucleobase enhance loss of the nucleobase [27]. Re-
cently, electrospray ionization tandem mass spectrom-
etry (ESI-MS/MS) has been used to study fragmenta-
tion of DNA adducts formed by the drug hedamycin
[28]. This study revealed primarily depurination of
hedamycin–guanine followed by cleavage of the phos-
phodiester backbone. From the MS/MS data, Iannitti
and co-workers determined the site of drug binding in
two different six-mers. In light of these observations, we
wanted to examine whether the utility of mass spec-
trometry could be further advanced; specifically, could
multiple stages of fragmentation be used to distinguish
isomeric oligonucleotides differing only in the site of
modification? Could it determine the identity of the
modification? For this purpose, we chose to examine
oligonucleotides modified at distinct sites with the
potent human carcinogen aflatoxin B1 (AFB1).
Upon metabolic activation to the exo-8,9-epoxide
[29], AFB1 forms DNA adducts predominantly at the
N7 position of guanines (AFB1–N7-Gua). The DNA
adducts formed by AFB1 are mutagenic [30, 31] and
exposure to AFB1 is correlated with an increased risk of
hepatocellular carcinoma [32]. Studies of AFB1–DNA
adducts have been hampered by the multiplicity of
adducts formed; treatment of an oligonucleotide con-
taining multiple guanines with AFB1 epoxide will result
in the formation of AFB1–N7-Gua adducts at any of the
guanines. Moreover, due to its positively charged imi-
dazole ring, AFB1–N7-Gua adducts are highly labile
and readily depurinate resulting in the formation of
apurinic (AP) sites. Alternatively, under mildly alkaline
conditions, the imidazole ring of AFB1–N7-Gua opens
to form the stable AFB1–formamidopyrimidine (AFB1–
FAPY) derivative33 (Scheme I). Thus, definitive charac-
terization of the molecular species present in a sample is
critical for any investigation of AFB1–DNA adducts.
In this work, a number of AFB1 monoadducts in the
sequence 59-CCGGAGGCC were analyzed by ESI-
ITMS. The MS/MS and MS3 capabilities of the ITMS
revealed not only the presence of intact AFB1–N7-Gua,
but also the site of modification within each oligonucle-
otide. Oligonucleotides containing a single AFB1–FAPY
adduct were also examined. In addition to having a
distinct molecular ion from the AFB1–N7-Gua, the
AFB1–FAPY exhibited a distinct cleavage pattern that
permitted differentiation of the two adducts.
Experimental
Oligonucleotide Preparation and Purification
DNA duplexes were reacted with AFB1 epoxide and
HPLC was used to separate and isolate the reaction
products as described by Essigmann and co-workers
[34]. The standard elution conditions allowed denatur-
ation of the duplexes, resolving the target strand from
their complements. By using this method, the comple-
mentary strands could be removed and the single-
stranded site-specifically AFB1-modified oligonucleo-
tides were isolated.
The oligonucleotide containing an AFB1–FAPY was
derived from the corresponding AFB1–N7-Gua contain-
ing oligonucleotide essentially as described [35]. The
AFB1–N7-Gua containing oligonucleotide was heated
for 4 h at 37°C in 10 mM sodium phosphate (pH 8.5).
The AFB1–FAPY oligonucleotide was purified using a
Nucleopak PA-100 strong ion exchange column (Di-
onex) eluted at 1.5 mL/min with a gradient of 30%–60%
B over 20 min (A 5 90:10 water/acetonitrile; B 5 1.5 M
NH4OAc in 90:10 water/acetonitrile). All samples were
desalted on Sep-pak C18 cartridges and eluted with
50% acetonitrile prior to mass spectrometric analysis.
Mass Spectrometry
The mass spectrometer used in all experiments was a
Finnigan LCQ (Finnigan, San Jose, CA) ion trap mass
spectrometer equipped with a Finnigan electrospray
ion source. The system was operated in the negative ion
mode with a spray voltage of 4.25 kV. The capillary
temperature was maintained at 200°C. A nitrogen
sheath gas was utilized. The oligonucleotides were
dissolved in 50:50 acetonitrile:water and infused at 2 mL
min21. Solutions of modified oligonucleotides were
approximately 10–20 mM. Each scan was the summa-
tion of three microscans with a maximum ion injection
time of 200 ms. Thirty scans were typically summed for
each spectrum. Helium gas was used as the collision gas
for the ion trap mass spectrometer.
Scheme I. AFB1 forms an epoxide and adducts at the N7
position of guanine. The result is AFB1–N7-Gua that can undergo
depurination to form an AP site or formation of the AFB1–FAPY
form under alkaline conditions.
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Results and Discussion
In these experiments, the unmodified oligonucleotide
59-CCGGAGGCC and derivatives containing either in-
tact AFB1–N7-Gua or AFB1–FAPY were analyzed by
ESI-ITMS. Oligonucleotides containing a single AFB1–
N7-Gua at different sites in this oligonucleotide se-
quence were synthesized by sequentially protecting
nondesired reaction sites with intercalation inhibitors
[34]. As a result, an improved yield was obtained for
each positional adduct that was isolated. Three samples
(referred to hereafter as chromatographic peaks A, B,
and C) corresponding to AFB1 monoadducts were ob-
tained after HPLC separation of the AFB1 epoxide
treated DNA. The peaks were collected off-line and
then individually infused into the ITMS. In addition to
the mass spectrometric analysis, the determination of
adduct location within the oligonucleotide was inde-
pendently confirmed by gel electrophoretic analysis
[34].
The nomenclature employed to describe oligonucle-
otide fragmentation was originally introduced by
McLuckey [23]. Cleavage across the phosphodiester
backbone results in the a–d series of ions containing the
59 end of the oligonucleotide and the w–z series ions
containing the 39 end. With oligonucleotides, the pre-
dominant backbone cleavage observed yielded the a-
base (B) and w ions [23, 24]. Figure 1 depicts the
MS/MS spectrum of the unmodified 9-mer oligonucle-
otide, 59-CCGGAGGCC. The [M–3H]32 ion at m/z 907
was selected and collided with helium gas. The result
was a large number of product ions, consistent with
previous investigations of oligonucleotides.
Figure 2 shows the full scan mass spectrum of
AFB1-modified peak A. The [M–2H]
22 and [M–3H]32
ions at m/z 1525 and 1016, respectively, confirm the
addition of AFB1 to the oligonucleotide. Collision in-
duced dissociation (CID) of the [M–3H]32 ion of the
modified oligomer A (Figure 3) resulted in the appear-
ance of the doubly and triply charged product ions
indicative of the loss of the modified guanine (AFB1–
N7-Gua) at m/z 1286 and 857. These product ions are
designated as [M–B*7]
22 and [M–B*7]
32, respectively.
Upon depurination, the resulting abasic site is suscep-
tible to cleavage of its 39 C–O bond, giving rise to the
intense product ion [a7–B*7]
22 at m/z 987. Also present
in the CID spectrum were the complementary w2
2
product ion at m/z 595 and the AFB1–N7-Gua ion at
m/z 478. The complementary product ions at m/z 595
and 987 revealed the site of base modification to be the
seventh nucleotide from the 59 end of the oligonucleo-
tide (G7).
The major ions observed in the tandem mass spec-
Figure 1. MS/MS spectrum of the [M–3H]32 ion of unmodified
59-CCGGAGGCC.
Figure 2. Full scan mass spectrum of AFB1–59–CCGGAGGCC
adduct peak A.
Figure 3. MS/MS spectrum of the [M–3H]32 ion at m/z 1016 of
AFB1–59–CCGGAGG*CC adduct peak A. Product ions revealed
the site of base modification to be the seventh nucleotide from the
59 end of the oligonucleotide. The modified base is designated
with an asterisk.
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trum in this investigation are consistent with earlier
studies of oligonucleotide fragmentation [23, 26]. In
those studies, loss of a nucleobase promoted fragmen-
tation at the 39 C–O bond of the sugar to which the base
was attached. Moreover, it has been shown that base
modification can significantly change the CID spectrum
for an oligonucleotide [27]. The pattern observed indi-
cates that increasing the electron affinity of the base
modification promotes loss of the base upon collision.
The presence of abundant m/z 1286 and 857 ions
(Figure 3) indicates the ease with which the AFB1
modified guanine may be eliminated upon collision.
This observation is not surprising since AFB1 modifica-
tion of guanine results in the formation of a positive
charge on the imidazole ring, which facilitates depuri-
nation of the AFB1–N7-Gua. A similar collision spec-
trum of an AFB1-modified oligomer has been reported
for the 6-mer ATG*CAT [36].
The full scan spectra of both peaks B and C also
displayed the [M–3H]32 ion of the modified oligomer at
m/z 1016 (data not shown). Collision of the [M–3H]32
ion (m/z 1016) of peak B led to loss of the AFB1–N7-
Gua ion with and without disruption of the oligonucle-
otide strand (Figure 4). As with peak A, loss of AFB1–
N7-Gua gave rise to peaks at m/z 1286 and 857.
However, other product ions unique to peak B pro-
vided insight into the position of the AFB1 modification.
Complementary ions corresponding to cleavage of the
C–O bond at the third sugar from the 59 end, m/z 947
and 675, indicated that peak B consists primarily of a
third base modification (G3). In addition, the presence
of the w5
22 ion at m/z 783 revealed that peak B may
have traces of an oligonucleotide modified at the fourth
base.
In addition to their “molecular” ions, normal full
scan spectra of both adduct peaks B and C also exhib-
ited product ions resulting from the degradation of the
modified oligomer. Specifically, the [a4–B*4]
2 product
ion at m/z 1004 and the AFB1–N7-Gua ion at m/z 478
are significantly abundant in the full scan spectrum of
adduct peak C without the application of collision
energy (data not shown). Observation of these product
ions is not surprising because the AFB1–N7-Gua is
labile and loss of AFB1–N7-Gua promotes fragmenta-
tion of the backbone. Figure 5 shows the collision of the
[M–3H]32 ion at m/z 1016 of adduct peak C. Besides
the m/z 1286 and 857 ions seen with each of the other
two isomers, the most prominent product ion in this
spectrum corresponds to the w5
22 ion at m/z 783, which
is the complement to the [a4–B*4]
2 ion at m/z 1004. The
presence of these product ions indicates that this sam-
ple is modified by AFB1 at the fourth base from the 59
end (G4).
In the case of adduct peak C, the sample concentra-
tion was adequate for the MSn capabilities of the ion
trap to be employed. By selecting and colliding the
depurinated oligonucleotide [M–B*4]
2 ion at m/z 1286,
the result was the generation of two complementary
product ions (Figure 6). These ions, m/z 1004 and 1566,
were produced by cleavage of the phosphodiester back-
bone at the site of modification and correspond to the
[a4–B*4]
2 and w5
2 product ions, respectively. This sim-
plified collision spectrum provided further evidence
that the AFB1 modification was attached to the guanine
in the fourth base position (G4) from the 59 end of the
sequence.
In addition to MS3 data on the modified oligonucle-
otide, multiple stages of collision were applied to the
AFB1–N7-Gua ion at m/z 478 from the full scan of
adduct peak C (Figure 7). MS/MS resulted in product
Figure 4. MS/MS spectrum of the [M–3H]32 ion at m/z 1016 of
AFB1–59–CCG*GAGGCC adduct peak B.
Figure 5. MS/MS spectrum of the [M–3H]32 ion at m/z 1016 of
AFB1–59–CCGG*AGGCC adduct peak C.
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ions at m/z 150 and 327 confirming the presence of
negatively charged guanine and AFB1, respectively. In
addition, the latter ion was selected and further collided
using MS3 capabilities. The product ions derived from
the ion at m/z 327 were similar to those previously
observed for AFB1 [29]. Thus, the fragmentation data
provided by the MS3 capabilities of the ITMS verified
that the covalent modification to the oligonucleotide
was indeed the addition of an intact AFB1 moiety.
Scheme II summarizes the predominant cleavage and
modification sites for each of the three AFB1-modified
isomers.
In addition to undergoing depurination, AFB1–N7-
Gua adducts can also be converted under alkaline
conditions to the more stable ring-opened AFB1–form-
amidopyrimidine (AFB1–FAPY) adduct. Thus, it was
important to establish that the mass spectrometry meth-
ods could be used to distinguish between AFB1–FAPY
and the parental AFB1–N7-Gua adducts. Accordingly,
two AFB1–FAPY containing oligonucleotides were ex-
amined, a 6-mer ATG*CAT and the 9-mer derived from
peak A, expected to contain an AFB1–FAPY at the 7th
base from the 59 end (G7). Comparison of the collision
spectra of the AFB1–N7-Gua and AFB1–FAPY modified
oligonucleotides revealed differences in their fragmen-
tation patterns consistent with their known solution-
phase chemical properties.
Figure 8 shows the spectrum generated from the
collision of the [M–3H]32 ion at m/z 711 of the AFB1–
FAPY containing ATG*CAT. The occurrence of the m/z
1211 ion confirms that the AFB1–FAPY modification is
part of the a3
2 ion, which contains the guanine. Interest-
ingly, the CID spectrum revealed fragmentation of the
Figure 6. MS3 spectrum (m/z 1016 3 m/z 1286 3 ?) of
[M–B*4]
22 ion. The result is cleavage of the phosphodiester back-
bone at the site of modification.
Figure 7. MS/MS spectrum of the AFB1–N7-Gua ion at m/z 478
and MS3 spectrum (m/z 478 3 m/z 327 3 ?) of the AFB1 ion.
Scheme II. Summary of fragmentation of the three AFB1-modi-
fied oligonucleotide isomers.
Figure 8. MS/MS spectrum of the [M–3H]32 ion at m/z 711 of
AFB1–FAPY–59–ATG*CAT.
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sugar–phosphate backbone at the third sugar without
loss of the modified guanine. The AFB1–FAPY adduct is
known to be more stable than the AFB1–N7-Gua adduct
because it does not contain a positively charged nitro-
gen center and thus remains bound to the 59 fragment.
Nevertheless, the presence of the base modification
resulted in preferential cleavage of the 39 C–O bond at
the modified base, as previously reported for other
modifications [26, 28, 36]. Subsequently, an oligonucle-
otide of the sequence 59-CCGGAGG*CC containing an
AFB1–FAPY at G7 was then analyzed to determine
whether cleavage of the 39 C–O bond of the modified
nucleotide is generally characteristic of AFB1–FAPY
fragmentation behavior.
The full scan of the AFB1–FAPY containing oligonu-
cleotide derived from peak A revealed ions at m/z 1022
and 1534 representing the [M–3H]32 and [M–2H]22
ions, respectively (data not shown). The corresponding
molecular weight indicated the presence of an AFB1–
FAPY moiety and not an AFB1–N7-Gua. In Figure 9,
collision of the [M–3H]32 ion at m/z 1022 displayed
two intense product ions at m/z 595 and 1236. These
complementary product ions represent the w2
2 and a7
22
ions, respectively, where the AFB1–FAPY guanine re-
mains bound to the 59 product ion. A less intense ion
corresponding to the [a7–B*7]
22 ion at m/z 987 was also
present, suggesting that some depurination had oc-
curred. The dominant fragmentation data from this
oligonucleotide, coupled with our observations of the
AFB1–FAPY 6-mer, suggested that preferential cleavage
of the 39 C–O bond without loss of the modified base
generally occurs with AFB1–FAPY modified oligonucle-
otides. This cleavage pattern contrasts sharply with that
observed for the intact AFB1–N7-Gua oligonucleotides,
which appear to cleave the phosphodiester backbone
after depurination.
Conclusion
Using MS/MS and MSn capabilities of the ITMS, we
were able to determine that each of three synthesized
isomeric oligonucleotides was modified at a single
guanine by AFB1. Moreover, from the distinctive frag-
mentation patterns obtained, it was possible to deter-
mine readily the site of modification within each oligo-
nucleotide and thus discern among the three structural
isomers. In addition, it was feasible to differentiate
between an AFB1–N7-Gua adduct and an AFB1–FAPY
derivative from both the molecular ions as well as the
fragmentation patterns. The increased stability of the
AFB1–FAPY as compared to the AFB1–N7-Gua adduct
was reflected by the product ions observed in the
collision spectra, suggesting that ESI-ITMS is applicable
to both stable and unstable DNA adducts. These studies
demonstrate that ESI-ITMS is a highly versatile method
that should be of great utility for identifying the struc-
ture, sequence location, and stability of DNA modifica-
tions. We are currently exploring different approaches
in order to increase the sensitivity of this system for the
analysis of in vitro or in vivo samples.
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